Pollen allergy
Conditions
Interventions
e-Diary (weekly)
Sponsors
Watanabe Yoshihiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written informed consent must be obtained before any assessment is performed 2. 12 years or older 3. Mentally competent and able to communicate verbally 4. Agree to provide informed consent (need assent if those are = 0.70 Ua/mL* by ImmunoCAP) and; a) have suffered from systemic symptoms (e.g., skin symptoms, gastrointestinal symptoms, headache, dizziness, fever, and palpitation) of pollen allergy OR b) have IgE-dependent food allergy caused by fruit, vegetable or soybean (2) For the respiratory symptom group: sensitized to pollen (specific IgE >= 0.70 Ua/mL* by ImmunoCAP) and have shown respiratory symptoms (nose, eye or cough; no systemic symptoms) of pollen allergy (3) For the symptom-free group: no any pollen allergy-induced symptoms regardless of sensitization
Exclusion criteria
Exclusion criteria: 1. Patients with a history of biologics use for immune disorders within one year prior to enrollment (biologic for asthma is allowed) 2. Patients with chronic respiratory diseases other than asthma, heart/renal diseases, autoimmune diseases requiring medication, inflammatory bowel disease, or malignant tumors 3. Patients with multiple chemical sensitivity defined by QEESI questionnaire Q1 >= 40 and Q3 >= 40 4. Other patients judged to be inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the subgroup as Latent Class | — |
Secondary
| Measure | Time frame |
|---|---|
| the factors specifying each subgroup | — |
Contacts
Public ContactNovartis Direct
Novartis Pharma. K.K.
Outcome results
None listed